Table 2 Underlying characteristics of overall survivors and participants of follow‐up surveys at 6 and 16 months
Characteristics | Overall survivors | At 6 months | At 16 months | ||||
|---|---|---|---|---|---|---|---|
n = 342 | n = 186 | n = 74 | |||||
n | % or (IQR) | n | % or (IQR) | n | % or (IQR) | ||
Age (year, median) | 45 | (31–60) | 46 | (30–59) | 48.5 | (35.6–60) | |
Sex | Male | 131 | 38.3 | 72 | 38.7 | 29 | 39.2 |
Female | 211 | 61.7 | 114 | 61.3 | 45 | 60.8 | |
Got infected | During Hospitalization | 76 | 22.2 | 26 | 14.0 | 9 | 12.1 |
While caring family at the hospital | 42 | 12.3 | 14 | 7.5 | 6 | 8.1 | |
During working in the hospital | 35 | 10.2 | 15 | 8.1 | 6 | 8.1 | |
In communities | 182 | 53.2 | 124 | 66.7 | 49 | 66.2 | |
Other | 2 | 0.6 | 4 | 2.2 | 3 | 4.1 | |
Unknown | 5 | 1.5 | 3 | 1.6 | 1 | 1.4 | |
Underlying conditions | Hypertension | 77/341 | 22.6 | 39 | 21.0 | 15 | 20.3 |
Diabetes | 28/340 | 8.2 | 13 | 7.0 | 4 | 5.4 | |
Chronic kidney disease | 28/340 | 8.2 | 9 | 4.8 | 2 | 2.7 | |
Chronic cardiac disease | 23/337 | 6.8 | 10 | 5.4 | 2 | 2.7 | |
Chronic liver disease | 5/340 | 1.5 | 3 | 1.6 | 0 | 0 | |
Malignant neoplasm | 3/340 | 0.9 | 2 | 1.1 | 0 | 0 | |
Chronic neurological disorder | 3/340 | 0.9 | 1 | 0.5 | 0 | 0 | |
Tuberculosis (previous) | 2/340 | 0.6 | 2 | 1.1 | 1 | 1.4 | |
HIV (not on ART) | 1/338 | 0.3 | 1 | 0.5 | 0 | 0 | |
Chronic pulmonary disease | 1/340 | 0.3 | 1 | 0.5 | 0 | 0 | |
Asthma | 0/340 | 0 | 0 | 0 | 0 | 0 | |
Current smoking | 0/339 | 0 | 0 | 0 | 0 | 0 | |
Tuberculosis (active) | 0/340 | 0 | 0 | 0 | 0 | 0 | |
Asplenia | 0/340 | 0 | 0 | 0 | 0 | 0 | |
Severity | Non-oxygen | 312/341 | 91.5 | 176 | 94.6 | 71/73 | 97.3 |
Oxygen therapy | 21/341 | 6.2 | 9 | 4.8 | 2/73 | 2.7 | |
Non-invasive ventilation | 2/341 | 0.6 | 0 | 0 | 0 | 0 | |
Invasive ventilation | 4/341 | 1.2 | 1 | 0.5 | 0 | 0 | |
ECMO | 2/341 | 0.6 | 0 | 0 | 0 | 0 | |
Outcome at discharge | Discharged alive | 322 | 94.2 | 182 | 97.8 | 73 | 98.6 |
Hospitalized | 8 | 2.3 | 3 | 1.6 | 0 | 0 | |
Transferred | 12 | 3.5 | 1 | 0.5 | 1 | 1.4 | |
COVID-19 vaccination status at 16 months* | 0 dose | NA | NA | NA | NA | 0 | 0 |
1 dose | NA | NA | NA | NA | 9 | 4.0 | |
2 doses | NA | NA | NA | NA | 60 | 81.1 | |
Unknown | NA | NA | NA | NA | 5 | 2.0 | |